Last reviewed · How we verify
NVP-2203
NVP-2203 is a small molecule that targets the PD-1 receptor.
NVP-2203 is a small molecule that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | NVP-2203 |
|---|---|
| Sponsor | NVP Healthcare |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, NVP-2203 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pruritus
Key clinical trials
- To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients (PHASE3)
- To Evaluate the Safety and the Pharmacokinetics of NVP-2203 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |